Company
Serilink specialises in the synthesis and modification of peptide/protein drugs and bioconjugations between small molecules and bio-macromolecules by utilising our in-house-developed patented novel technology (OPA LinkTech). We are focused on building a high-tech biologic therapeutics research platform for developing antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), and peptide-drug conjugates (PDCs).
Description
Serilink Biotechnology Company offers an R&D platform specialised in conjugation drugs, (ADCs, ARCs, PDCs etc.)
